Wednesday, Evotec SE (NASDAQ:EVO) reported sales of $201.12 million (182.12 million euros), up from 170.28 million euros reported a year ago. The German drug maker reported an EPS loss of 54 cents, down from 8 cents a year ago. Also Read: German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount. “However, H1 2024 revenues and profitability have been more challenging for the company than expected. We are operating in a more difficult market environment, most notably the slowdown of early-stage R&D spending,” said Christian Wojczewski, CEO of ...